Mizuho Coverage Launch: Mizuho has started coverage on the biotech firm with an outperform rating and a $14 price target, well above the current trading level near $5.50. The move centers on encouraging progress with bempikibart, the lead alopecia areata therapy. Social media observers note that fresh Phase II data expected in mid-2026 could further strengthen the drug's profile as a non-JAK inhibitor option.
Drug Development Focus: Market participants highlight the candidate's proof-of-concept data in alopecia areata and its potential to compete in a space dominated by other mechanisms. Discussions emphasize positioning for possible registrational trials within the next six to twelve months. Commentary reflects measured optimism around the timeline and competitive edge.
Broader Sentiment Trends: Overall chatter on social media shows growing attention to the stock following the analyst note, with users pointing to the sizable upside implied by the new target. Some reference prior under-the-radar interest in the pipeline. The tone remains constructive yet grounded in the need for upcoming clinical updates.
Note: This discussion summary was generated from an AI condensation of post data.
Q32 Bio Insider Trading Activity
Q32 Bio insiders have traded $QTTB stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $QTTB stock by insiders over the last 6 months:
- JODIE POPE MORRISON (CEO) has made 0 purchases and 2 sales selling 32,402 shares for an estimated $122,545.
- LEE KALOWSKI (CFO and President) has made 0 purchases and 2 sales selling 13,067 shares for an estimated $49,430.
- SHELIA M. VIOLETTE (Chief Scientific Officer) sold 2,815 shares for an estimated $12,708
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Q32 Bio Hedge Fund Activity
We have seen 24 institutional investors add shares of Q32 Bio stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OPALEYE MANAGEMENT INC. added 1,042,865 shares (+488.8%) to their portfolio in Q1 2026, for an estimated $6,695,193
- MACKENZIE FINANCIAL CORP added 246,304 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,581,271
- ACORN CAPITAL ADVISORS, LLC removed 178,373 shares (-36.1%) from their portfolio in Q1 2026, for an estimated $1,145,154
- MONIMUS CAPITAL MANAGEMENT, LP added 134,310 shares (+inf%) to their portfolio in Q1 2026, for an estimated $862,270
- TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK removed 133,903 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $444,557
- ACADIAN ASSET MANAGEMENT LLC added 124,213 shares (+256.8%) to their portfolio in Q1 2026, for an estimated $797,447
- RENAISSANCE TECHNOLOGIES LLC added 107,315 shares (+107.7%) to their portfolio in Q1 2026, for an estimated $688,962
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Q32 Bio Analyst Ratings
Wall Street analysts have issued reports on $QTTB in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 05/22/2026
- Cantor Fitzgerald issued a "Overweight" rating on 05/18/2026
To track analyst ratings and price targets for Q32 Bio, check out Quiver Quantitative's $QTTB forecast page.
Q32 Bio Price Targets
Multiple analysts have issued price targets for $QTTB recently. We have seen 2 analysts offer price targets for $QTTB in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Joseph Catanzaro from Mizuho set a target price of $14.0 on 05/22/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $13.0 on 05/05/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
